Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma

Journal of Clinical Pharmacology

Volumn 50, Issue 10, 2010, Pages 1118-1127

  Xu, Jian ^a   Nave, Rüdiger ^b   Lahu, Gezim ^b   Derom, Eric ^c   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Nycomed GmbH   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

asthma; ciclesonide; cortisol suppression; fluticasone propionate; inhaled corticosteroids; Population pharmacokinetics and pharmacodynamics

Indexed keywords

CICLESONIDE; FLUTICASONE PROPIONATE; PLACEBO; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE REGIMEN; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PREGNENEDIONES; SEX FACTORS;

EID: 77958576764     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009354994     Document Type: Article

References (21)

1. Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma: summary report 2007. J Allergy Clin Immunol. 2007 ; 120 (5 suppl). S94 - S138.
2. Toogood JH Side effects of inhaled corticosteroids. J Allergy Clin Immunol. 1998 ; 102 (5). 705-713.
3. Dietzel K., Engelstätter R., Keller A. Ciclesonide: an on-site-activated steroid. In: Hansel TT, Barnes PJ, eds. New Drugs for Asthma, Allergy and COPD: Progress Respiratory Research. Vol. 31. Basel, Switzerland: Karger ; 2001: 91-93.
4. Rohatagi S., Krishnaswami S., Pfister M., Sahasranaman S. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. Am J Ther. 2005 ; 12 (5). 385-397.
5. Mollmann H., Wagner M., Meibohm B., et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol. 1998 ; 53 (6). 459-467.
6. Derom E., Louis R., Tiesler C., Engelstatter R., Kaufman JM, Joos GF Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J. 2009 ; 33 (6). 1277-1286.
7. Mascher HJ, Zech K., Mascher DG Sensitive simultaneous determination of ciclesonide, ciclesonide-M1-metabolite and fluticasone propionate in human serum by HPLC-MS/MS with APPI. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 ; 869 (1-2). 84-92.
8. Rohatagi S., Bye A., Mackie AE, Derendorf H. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci. 1996 ; 4 (6). 341-350.
9. Derendorf H., Mollmann H., Barth J., Mollmann C., Tunn S., Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol. 1991 ; 31 (5). 473-476.
10. Derendorf H., Hochhaus G., Meibohm B., Mollmann H., Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998 ; 101 (4 pt 2). S440 - S446.
11. Rohatagi S., Arya V., Zech K., et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol. 2003 ; 43 (4). 365-378.
12. Derendorf H., Hochhaus G. What is the best marker for inhaled corticosteroid safety ? Allergy Asthma Proc. 2005 ; 26 (2). 89-93.
13. Rohatagi S., Bye A., Falcoz C., et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol. 1996 ; 36 (10). 938-941.
14. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1996 ; 41 (6). 539-542. (Pubitemid 26184675)
15. Gu Z., Zhao XG, Nave R., et al. Comparative in vitro metabolism of 14C-ciclesonide in hepatocytes from the mouse, rat, rabbit, dog, and human. Am J Ther. 2007 ; 14 (3). 280-290.
16. Bernstein DI, Allen DB Evaluation of tests of hypothalamic-pituitary- adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007 ; 98 (2). 118-127.
17. Xu J., Sabarinath SN, Derendorf H. Cortisol suppression as a surrogate marker for inhaled corticosteroid-induced growth retardation in children. Eur J Pharm Sci. 2009 ; 36 (1). 110-121.
18. Derom E., Van De Velde V., Marissens S., Engelstatter R., Vincken W., Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005 ; 18 (5). 328-336.
19. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 2005 ; 94 (4). 465-472.
20. Szefler S., Rohatagi S., Williams J., Lloyd M., Kundu S., Banerji D. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary- adrenal axis function in patients with moderate-to-severe persistent asthma. Chest. 2005 ; 128 (3). 1104-1114.
21. Weinbrenner A., Huneke D., Zschiesche M., et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab. 2002 ; 87 (5). 2160-2163.